Drugs / TQB3455
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04340427 | Apr 2020 → Jun 2021 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06550713 | Oct 2019 → Dec 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3455 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06550713 ↗ |
| Action | Inhibit | “TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.” NCT04340427 ↗ |
| Modality | Small molecule | “TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.” NCT04340427 ↗ |
| Route | Oral | “TQB3455 Tablet administered orally once.” NCT04340427 ↗ |
| Target | IDH2 | “TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.” NCT04340427 ↗ |